10 Best Gene Therapy Stocks to Buy Right Now

6) Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 24

Beam Therapeutics Inc. (NASDAQ:BEAM) leverages advanced base editing technology to develop innovative therapies targeting genetic diseases. Its approach allows for precise and permanent modifications of DNA at the single-base level.

Beam Therapeutics Inc. (NASDAQ:BEAM)’s most advanced program, BEAM-101 for sickle cell disease (SCD), demonstrated promising early results. Rapid engraftment and high levels of fetal hemoglobin (HbF) in treated patients were observed, potentially outperforming other gene therapies in development. By reactivating the production of HbF, BEAM-101 focuses on alleviating the symptoms of SCD by reducing the presence of sickled red blood cells and improving oxygen delivery.

Current treatments, like hydroxyurea and chronic transfusions, tend to manage symptoms but do not address the root cause. This provides a significant opportunity for transformative therapies like BEAM-101. By permanently reactivating HbF, BEAM-101 can reduce the need for ongoing medical interventions and improve patients’ quality of life.

Beam Therapeutics Inc. (NASDAQ:BEAM)’s newly developed automated CD34+ cell process for BEAM-101 manufacturing is expected to revolutionize gene therapy. By increasing process capacity threefold, maintaining high consistency and reducing contamination risk simultaneously, Beam Therapeutics Inc. (NASDAQ:BEAM) can produce its therapies more efficiently and cost-effectively than competitors. Some of the competitive advantages include improved scalability, reduced production costs, and enhanced product consistency.